APP Pharmaceuticals Announces Trading Information on NASDAQ of Contingent Value Rights Associated with the Acquisition by Fresenius

Business Wire, Sept 10, 2008

SCHAUMBURG, Ill. -- APP Pharmaceuticals, Inc., formerly traded on the NASDAQ Capital Market under the symbol APPX, today announced that the NASDAQ Global Market has accepted for listing the Contingent Value Rights (CVRs) related to the acquisition of APP by Fresenius Kabi, a business segment of Fresenius SE. The CVRs will trade under the symbol "APCVZ" beginning on Thursday, September 11, 2008.

The acquisition of APP was completed earlier today. On July 7, 2008, Fresenius announced the agreement to acquire Schaumburg, Illinois-based APP Pharmaceuticals, Inc. Under the terms of the agreement, Fresenius acquired the outstanding common stock of APP for $23.00 in cash per share (the "Cash Purchase Price") plus a CVR that could deliver up to an additional $980 million, or $6.00 per CVR in cash, if the financial results of APP meet certain targets (payable in Q2 2011).

About Fresenius SE

Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care. In 2007, group sales were approximately [euro] 11.4 billion. On June 30, 2008 the Fresenius Group had 117,453 employees worldwide. For more information visit the company's website at www.fresenius.com.

About Fresenius Kabi

Fresenius Kabi is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. Fresenius Kabi's core product range includes infusion solutions for fluid substitution, blood volume expansion and parenteral nutrition, as well as products for enteral nutrition. Furthermore, the company provides concepts for ambulatory health care and is focused on managing and providing home therapies. With its philosophy "Caring for life" and a comprehensive product portfolio, the company aims at improving the quality of life of patients all over the world. On June 30, 2008 the company had 18,323 employees. In 2007, Fresenius Kabi achieved sales of [euro] 2,030 million and an operating profit of [euro] 332 million. Fresenius Kabi AG is a 100% subsidiary of the health care group Fresenius SE.

About APP Pharmaceuticals, Inc.

APP is a fully-integrated pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. The company offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations.

Forward-Looking Statement

The statements contained in this news release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this news release include statements regarding the closing of the transaction; the result of the review of the transaction by various regulatory agencies; existing and possible future litigation relating to the transaction, our expectations, beliefs, hopes, goals, intentions, initiatives or strategies. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, the availability and pricing of ingredients used in the manufacture of pharmaceutical products and the ability to successfully manufacture products in a time-sensitive and cost effective manner. Additional relevant information concerning risks can be found in the APP, Inc. Form 10-K for the year ended December 31, 2007 and other documents the company has filed with the Securities and Exchange Commission.

In connection with the proposed merger, Fresenius Kabi Pharmaceuticals Holding, Inc. and APP have filed relevant materials with the SEC, including a registration statement that contains a joint prospectus and information statement. Investors and security holders are urged to read these documents and any other relevant documents filed with the SEC, as well as any amendments or supplements to those documents, because they contain important information. Investors and security holders may obtain these documents free of charge at the SEC's website at www.sec.gov. Investors and security holders are urged to read the joint information statement/prospectus and the other relevant materials before making any investment decision with respect to the proposed merger.

The information contained in this news release is as of the date of this release. Neither Fresenius nor APP assumes any obligation to update any forward-looking statements contained in this press release as the result of new information or future events or developments.